Israel-based software company Medial EarlySign will work with Geisinger's innovation center to develop technologies to predict lower GI and other "high-burden" diseases.
The new partnership also gives clinical Dx analytics firm Prognos access to Datavant's pharma and biotech customers.
Singapore-based Lucence Diagnostics will team with Stanford to analyze sequencing and imaging of liver cancer patients to predict therapeutic effectiveness.
The Clinical Treatment Score post-5-years tool helps clinicians identify which patients are at high risk of their cancers recurring after completing five years of adjuvant hormone therapy.
Clew Medical aggregates data from multiple devices and information systems to identify and refine patterns that indicate patient deterioration.